New Treatment for Plaque Psoriasis Approved in Europe – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
Almirall has received European Commission approval for its plaque psoriasis treatment tildrakizumab (Ilumetri), Sun Pharma announced in a press release.
Tildrakizumab, a humanized high-affinity anti-IL-23p19 monoclonal antibody, is indicated for the treatment of adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy. Sun Pharma out-licensed tildrakizumab to Almirall for the development and commercialization of the product for psoriasis in Europe.
The drug’s European approval is based on data from the reSURFACE 1 and 3 phase 3 clinical trials, which included 1800 patients from more than 200 clinical sites worldwide and evaluated tildrakizumab’s safety and efficacy.